Effect of antidiabetic therapy on TNF-α, IL-18, IL-23 and IL-35 levels in T2DM patients with coincidental <i>Helicobacter pylori</i> infection

Abdel-Moneim, Adel; El‐Twab, Sanaa M. Abd; Nabil, Ahmed; Kazafy, Salma A. El

doi:10.1080/16583655.2020.1824669

Cited by 4 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Type 2 diabetes mellitus (T2DM) is a disease characterized by hyperglycemia and insulin receptor dysfunction due to impaired lipid and carbohydrate metabolism which causes excess glycogen deposition and rejection of insulin resistance. (1,2) Currently, diabetes which is closely related to obesity has become a global epidemic. Adipose tissue is known as a major contributor to the production of pro-inflammatory molecules such as tumor necrosis factor alpha (TNF-α), interleukin-18 (IL-18), interleukin-1 (IL-1), interleukin-6 (IL-6) and C-reactive protein (CRP) trigger the progression of kidney failure.…”

Section: Introductionmentioning

confidence: 99%

“…(7,8) Tumor necrosis factor-alpha is one of the key pro-inflammatory cytokines that contribute to the development of insulin resistance and T2DM through activating lowgrade inflammation by decreasing glucose transporter-4 (GLUT4) and serine phosphorylation of insulin receptor substrate-1 (IRS-1) expression. (2) Approximately 30% of patients with type 1 DM (T1DM) and 40% of patients with type 2 DM (T2DM) develop a diabetic kidney disease (DKD). (1,6,9) The prevalence is estimated to have reached 537 million people worldwide and is projected to increase to 643 million people in 2030.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Secretome hypoxia-mesenchymal stem cells decrease tumor necrosis factor-α and interleukin-18 in kidney of type 2 diabetes mellitus model rats

Irawan,

Putra,

Setyo

et al. 2023

Univ Med

View full text Add to dashboard Cite

Background Type 2 diabetes mellitus (T2DM) is a chronic disease that affects millions of people worldwide and associated with an increased risk of kidney damage caused by prolonged inflammation. Secretome hypoxia- mesenchymal stem cells (SH-MSCs) have been investigated as a potential therapy for kidney inflammation in T2DM, due to their immunomodulatory properties and ability to promote tissue repair. In this study, we investigated the effects of SH-MSCs on tumor necrosis α (TNF-á) and interleukin-18 (IL-18) in the kidney of the T2DM model rats. MethodsA post-test-only control group involving 24 male Wistar rats. The rats were treated with a high-fat diet (HFD) for 4 weeks and streptozotocin-nicotinamide with sucrose solution for 5 days to induce T2DM animal models. Rats were randomly divided into four groups: healthy, control, and groups treated with SH-MSCs T1 and T2, with doses of 250 µL and 500 µL, respectively. TNF-α and IL-18 gene expression was measured by real time polymerase chain reaction (RT-PCR). One Way ANOVA and post-hoc LSD tests were used to determine the significant difference against all groups based on their quantitative measurement. ResultsAdministration of the SH-MSCs at a dose of 500µL (T2) was able to significantly reduce TNF-α and IL-18 gene expression when compared to control (T2DM rat without treatment) (p<0.05), but not significantly when compared to healthy and SH-MSC at a dose of 250µL (T1) group (p >0.05). ConclusionThis study demonstrated that the SH-MSCs decreased the levels of proinflammatory cytokines TNF-α and IL-18 gene expression in the kidney of T2DM model rats.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Secretome hypoxia-mesenchymal stem cells decrease tumor necrosis factor-α and interleukin-18 in kidney of type 2 diabetes mellitus model rats

Irawan,

Putra,

Setyo

et al. 2023

Univ Med

View full text Add to dashboard Cite

show abstract

Efficacy of metformin on different adipocytokines in type 2 diabetes mellitus patients

Hamdy,

Abdel-Gabbar,

Sakr

et al. 2024

Egyptian Pharmaceutical Journal

View full text Add to dashboard Cite

Background Type 2 diabetes mellitus is a major medical condition that constitutes a significant financial burden on most healthcare systems. Objective The current research aimed to evaluate the antidiabetic, anti-inflammatory, and antihyperlipidemic effects of 500 mg metformin twice daily for 6 months on various adipocytokines in type 2 diabetes mellitus patients. Patients and methods The participants in this study were divided into three groups: the control, the untreated diabetic, and the metformin-treated diabetic groups. Results and conclusion Metformin treatment significantly improved the poor oral glucose tolerance and the lowered serum levels of insulin and C-peptide with subsequent better homeostatic model assessment for insulin resistance and sensitivity and β-cell function results. Moreover, metformin treatment significantly decreased the elevated serum levels of glycosylated hemoglobin, high, low, and very low-density lipoproteins, adipokines (visfatin and resistin), and retinol-binding protein-4 expression, with a significant increase in total cholesterol and triglycerides. Metformin also reduced the proinflammatory cytokine expressions (interleukin-1β, interferon-γ, and tumor-necrosis factor-α). In conclusion, metformin can alleviate adipocytokines through anti-inflammatory effects, synergizing with its antidiabetic actions.

show abstract

Comparison of Serum Interleukin-37 Level in Obese, Nonobese Type II Diabetic Patients and Healthy Controls

Alhayali

Yucel²,

Ashoor

2021

Mustansiriya Medical Journal

View full text Add to dashboard Cite

Backgroud: Type 2 diabetes mellitus (DM2) is a metabolic disease resulting from the genetic and environmental factors and which causes insulin dysfunction on peripheral tissues, as well as in the pancreatic β-cell. Underlying pathologies such as overweight and obesity are the main factors for the development of T2DM. Interleukin-37 (IL-37) is an anti-inflammatory cytokine and also called as a “dual function.” Aim of study: This study has demonstrated was elevated in the obese T2DM patients and IL-37 protects from obesity-induced leading to development of T2DM. Fifty-eight patients who visited to the National Center for Diabetes Research and Treatment in the İraq/Baghdad with the age of <40–>60 years were employed in this study. Patient groups were 29 obese T2DM and 29 nonobese T2DM patients, and they when compared with 29 individuals as healthy control groups. In this study, serum IL-37 levels were determined by enzyme linked immunosorbent assay. Results: In obese T2DM patients, the mean serum level of IL-37 was elevated and significantly higher (mean ± standard deviation [SD], 5.594 ± 3.421 pg/ml; P < 0.0001) in comparison with nonobese T2DM patients (mean ± SD, 1.851 ± 0.417 pg/ml; P < 0.0001) and healthy control group (mean ± SD, 0.777 ± 0.099 pg/ml). Conclusions: In this study, obese T2DM patients had higher serum IL-37 levels but lower serum IL-37 levels in nonobese diabetic patients as compared to the healthy controls. This result led to the supposition that the rise in serum IL-37 level is related with obesity. Further, it suggests that IL-37 being an anti-inflammatory mediator might be responsible for some underline changes, which may develop the progress of T2DM.

show abstract

Effect of antidiabetic therapy on TNF-α, IL-18, IL-23 and IL-35 levels in T2DM patients with coincidental Helicobacter pylori infection

Cited by 4 publications

References 43 publications

Secretome hypoxia-mesenchymal stem cells decrease tumor necrosis factor-α and interleukin-18 in kidney of type 2 diabetes mellitus model rats

Secretome hypoxia-mesenchymal stem cells decrease tumor necrosis factor-α and interleukin-18 in kidney of type 2 diabetes mellitus model rats

Efficacy of metformin on different adipocytokines in type 2 diabetes mellitus patients

Comparison of Serum Interleukin-37 Level in Obese, Nonobese Type II Diabetic Patients and Healthy Controls

Contact Info

Product

Resources

About